The symplicity htn3 study is a, multicenter, prospective, singleblind, randomized, controlled study of the safety and effectiveness of renal denervation in subjects with uncontrolled hypertension. The change in 24hour ambulatory systolic blood pressure was. Percutaneous renal denervation in patients with treatment. The symplicity htn2 trial renal sympathetic denervation in patients with treatmentresistant hypertension is summarized in this section including the primary endpoint and results. Aug 17, 2011 the symplicity htn 3 study is a, multicenter, prospective, singleblind, randomized, controlled study of the safety and effectiveness of renal denervation in subjects with uncontrolled hypertension. At 36 months, 88 patients in symplicity htn 1, a proofofconcept firstinman registry, achieved a 3214 mmhg reduction in blood pressure from baseline. Symplicity htn3 was the best designed and largest randomised trial of rdn in resistant hypertension to date and demonstrated that rdn achieved a reduction of blood pressure in patients with resistant hypertension that was large in absolute terms but rendered nonsignificant when compared to the equally large drop of blood pressure in the sham group. Renal sympathetic denervation in patients with treatment. Request pdf on may 31, 2014, rahman shah and others published renal denervation for resistant hypertension the symplicity htn 1 study find, read and cite all the research you need on. Renal denervation in patients with refractory hypertension htn1 the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. The symplicity htn 2 trial renal sympathetic denervation in patients with treatmentresistant hypertension is summarized in this section including the primary endpoint and results. Nov 17, 2010 symplicity htn 2 was an international, multicentre, randomised study of the safety and effectiveness of renal denervation in patients with treatmentresistant hypertension. The symplicity htn 3 randomized, blinded, shamcontrolled trial confirmed the safety of renal denervation rdn, but did not meet its primary efficacy endpoint.
Percutaneous renal denervation in patients with treatmentresistant hypertension. Symplicity htn3 is the companys united states pivotal trial in renal denervation for treatmentresistant hypertension. Oneyear data from symplicity htn 3 confirm findings from six month analysis 2 september 2014 longerterm followup data from the symplicity htn 3 trial confirmed both the safety and absence. Oneyear data from symplicity htn3 confirm findings from. The primary goal of simplicity health is to provide ongoing primary care, prevention, and disease management for chronic illnesses like diabetes, hypertension and heart disease. Predictors of blood pressure response in the symplicity. Apr 23, 2008 renal denervation in patients with refractory hypertension htn 1 the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. A controlled trial of renal denervation for resistant. Medtronics symplicity htn3 pivotal trial fails to meet. Listing a study does not mean it has been evaluated by the u. Symplicity htn3 renal denervation in patients with. Evaluated renal sympathetic denervation versus no treatment in patients with blood pressure 160 mmhg despite 3 antihypertensive medications. Medtronic states that the trial met its primary safety endpoint, and the trials data safety monitoring board concluded that there were no safety concerns in the study.
Staff will assist patients who need to arrange for additional services beyond the primary care offered at simplicity health clinics. Bilateral renal denervation will be performed using the symplicity catheter a percutaneous system that delivers radiofrequency rfenergy through the luminal surface of the renal artery. Bilateral renal denervation will be performed using the symplicity catheter a percutaneous system that delivers radiofrequency rfenergy. Patients aged 1885 years with a systolic blood pressure of 160 mm hg or more. While relatively small in size, the study suggested that catheterbased renal denervation using a firstgeneration single electrode catheter appeared safe and was associated with a significant reduction in office blood pressure at six, 12, and 36 months postintervention, respectively. Symplicity htn2 was an international, multicentre, randomised study of the safety and effectiveness of renal denervation in patients with treatmentresistant hypertension. Every randomization was proctored by a monitor, so that when youre on the cath lab table, every person in symplicity htn 3 whether. The publication of symplicity htn1 triggered substantial interest and enthusiasm in the hypertension community. One of the pis and other experts take a stab at what went wrong. Symplicity htn 3, the renaldenervation trial for resistant hypertension, turned out to be not so simple after all. While symplicity htn 1 and htn2 found a substantial reduction in blood pressure with renal denervation, symplicity htn 3the largest and first study to include a sham controlfailed to demonstrate a blood pressure lowering effect beyond that observed in the sham control group.
Microsoft word employer guide to using symplicity for website1. The design of the symplicity htn 3 trial has been reported previously. Symplicity htn 1 1 and symplicity htn 2 2 demonstrated that renal denervation rdn could achieve a significant reduction in office blood pressure in patients with resistant hypertension. Prior rdn studies have demonstrated significant and durable reductions in blood pressure. Request pdf on may 31, 2014, henry krum and others published renal denervation for resistant hypertension the symplicity htn 1 study reply find, read and cite all the research you need on. Renal denervation in patients with refractory hypertension.
1386 504 1227 1090 208 347 264 963 1490 734 598 401 1018 374 1181 806 874 336 649 1346 779 1004 1233 1463 829 1049 378 120 1178 191 1286 810 1183 1225 958 1111